

REGISTERED NUMBER: 11463856 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

FOR

PANDEIA THERAPEUTICS LIMITED

CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 December 2020

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

COMPANY INFORMATION
for the Year Ended 31 December 2020

DIRECTORS:

Dr J F Murray
Dr D J Grainger
F De Rubertis

SECRETARY:

The Cambridge Partnership Limited

REGISTERED OFFICE:

C/o The Cambridge Partnership Ltd
The Dorothy Hodgkin Building
Babraham Research Campus, Babraham
Cambridge
Cambridgeshire
CB22 3FH

REGISTERED NUMBER:

11463856 (England and Wales)

ACCOUNTANTS:

Lovetts Chartered Accountants
Bridge House
25 Fiddlebridge Lane
Hatfield
Hertfordshire
AL10 0SP

BALANCE SHEET
31 December 2020

	Notes	31.12.20 £	£	31.12.19 £	£
FIXED ASSETS					
Tangible assets	4		1,722		2,182
CURRENT ASSETS					
Debtors	5	513,110		175,664	
Cash at bank		<u>364,357</u>		<u>1,385,926</u>	
		877,467		1,561,590	
CREDITORS					
Amounts falling due within one year	6	<u>134,111</u>		<u>157,043</u>	
NET CURRENT ASSETS			<u>743,356</u>		<u>1,404,547</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>745,078</u>		<u>1,406,729</u>
CAPITAL AND RESERVES					
Called up share capital			3,041		2,196
Share premium			2,592,405		1,748,250
Retained earnings			<u>(1,850,368)</u>		<u>(343,717)</u>
			<u>745,078</u>		<u>1,406,729</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 February 2021 and were signed on its behalf by:

Dr J F Murray - Director

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 December 2020

1. **STATUTORY INFORMATION**

Pandeia Therapeutics Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 20% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 December 2020

2. **ACCOUNTING POLICIES - continued**

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 3 (2019 - 1) .

4. **TANGIBLE FIXED ASSETS**

Computer
equipment
£

COST

At 1 January 2020
and 31 December 2020

2,298

DEPRECIATION

At 1 January 2020

116

Charge for year

460

At 31 December 2020

576

NET BOOK VALUE

At 31 December 2020

1,722

At 31 December 2019

2,182

5. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.20	31.12.19
	£	£
Trade debtors	1,487	7,009
Other debtors	<u>511,623</u>	<u>168,655</u>
	<u>513,110</u>	<u>175,664</u>

6. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.20	31.12.19
	£	£
Trade creditors	128,423	145,004
Other creditors	<u>5,688</u>	<u>12,039</u>
	<u>134,111</u>	<u>157,043</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.